Syndrome of inappropriate secretion of antidiuretic hormone (Q39843): Difference between revisions

← Older edit

@@ Property / Canonical URI @@
+https://id.who.int/icd/entity/550787432
@@ Property / Canonical URI: https://id.who.int/icd/entity/550787432 / rank @@
+Normal rank
@@ Property / CURIE @@
+CID11:5A60.2
@@ Property / CURIE: CID11:5A60.2 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-5A60.2
@@ Property / Canary Token: dki-india-5A60.2 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank
@@ Property / Linked ICD 10 @@
+E22.2
@@ Property / Linked ICD 10: E22.2 / rank @@
+Normal rank

Latest revision as of 05:24, 13 August 2026

Syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) is characterised by continued ADH secretion, leading to hyponatremia, hypoosmolality and natriuresis. Exact prevalence is unknown. The disease has been described in all age groups. SIADH is often associated with tumours, pulmonary disease, central nervous system disorders or exposure to drugs. Occasionally, it is found in patients with adrenal, thyroid or pituitary insufficiency. The disorder is caused by gain-of-function mutations in the gene encoding the vasopressin V2 receptor. Fluid restriction is the most common treatment. The outcome is related to the underlying and associated disorders.

Language	Label	Description	Also known as
default for all languages	5A60.2
English	Syndrome of inappropriate secretion of antidiuretic hormone	Syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) is characterised by continued ADH secretion, leading to hyponatremia, hypoosmolality and natriuresis. Exact prevalence is unknown. The disease has been described in all age groups. SIADH is often associated with tumours, pulmonary disease, central nervous system disorders or exposure to drugs. Occasionally, it is found in patients with adrenal, thyroid or pituitary insufficiency. The disorder is caused by gain-of-function mutations in the gene encoding the vasopressin V2 receptor. Fluid restriction is the most common treatment. The outcome is related to the underlying and associated disorders.